Eli Lilly’s Neuro Prospects Expand to Sleep Science With $6.3B Centessa Acquisition

Frank Vinluan / medcitynews - Centessa Pharmaceuticals’ cleminorexton is part of the orexin agonist drug class, which could introduce a new approach to the treatment of narcolepsy and other sleep disorders. Acquiring Centessa brings Eli Lilly into a group of clinical-stage orexin agon…

AI Summary: Eli Lilly announced a $6.3 billion acquisition of Centessa to secure a promising narcolepsy/sleep-disorder candidate and expand its neuroscience portfolio. The deal fast-tracks Lilly into sleep science, buying late-stage assets rather than relying on in-house miracles — a tidy shortcut to diversifying its neurotherapeutics pipeline.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Chiesi acquires KalVista for $1.9B to bolster rare disease pipeline / 29 days

Biogen announces $5.6B acquisition of Apellis Pharma / 1 month

Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 2 months

Novartis closes Avidity deal; Atrium Therapeutics spinout launches / 2 months

Eli Lilly buys Orna to sprint into in‑vivo CAR‑T therapeutics / 3 months

Eli Lilly acquires CrossBridge Bio in oncology deal up to $300M / 6 wks

Neurocrine buys Soleno Therapeutics for $2.9B to gain Prader‑Willi drug / 7 wks